Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03037983 · ClinicalTrials.gov registry record · NA

Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation

A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
9
Enrollment target
1
Study location

NCT03037983 is a NA study of Schizophrenia and Schizoaffective Disorder that has completed, run by VA Office of Research and Development. The registered enrollment target is 9 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03037983, a NA study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether repetitive transcranial magnetic stimulation (rTMS) is effective in remediating cognitive deficits while also improving functionality in Veterans with schizophrenia.

Interventions

  • DEVICE Sham
  • DEVICE Repetitive transcranial magnetic stimulation

Study Locations (1)

California

  • VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2017-08-01
Est. Completion 2019-07-18
Phase NA

Sponsor

VA Office of Research and Development

1,668 total trials

What the Registry Record Tells You About NCT03037983

The ClinicalTrials.gov registry entry for NCT03037983 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (96% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.

NCT03037983 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03037983 about?

NCT03037983 is a clinical study titled "Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation". The purpose of this study is to determine whether repetitive transcranial magnetic stimulation (rTMS) is effective in remediating cognitive deficits while also improving functionality in Veterans with schizophrenia.

What is the current status of trial NCT03037983?

This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2017-08-01. Estimated completion is 2019-07-18.

What conditions does trial NCT03037983 study?

This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.

What interventions are being tested in trial NCT03037983?

The interventions under investigation include: Sham (DEVICE), Repetitive transcranial magnetic stimulation (DEVICE).

Who is sponsoring clinical trial NCT03037983?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03037983 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.